Clinical Trial Update: Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD) [Phase 2]

View source ↗

Summary

Phase 2 study assessing the safety of dupilumab (REGN668/SAR231893) given with topical corticosteroids in adults with moderate-to-severe atopic dermatitis; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Dupilumab (dupilumab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Atopic Dermatitis | Phase 2 | Status: COMPLETED | Results posted: 2017-10-13